Highest-materiality recent filing
Lifeward issues $5.58M initial convertible notes; additional $5.58M contingent on milestones
Initial $5.58M senior secured convertible notes at 8% interest, convertible at $5.40/share.
Lifeward Q1 revenue down 22%, net loss widens to $10.8M; cash improves to $11.4M
Revenue $3.9M (down 22% YoY); AlterG sales fell 38% to $2.1M on supply chain timing.
Lifeward completes acquisition of Oratech Pharma, issues shares and convertible notes
Lifeward completed acquisition of Oratech Pharma on March 25, 2026, issuing 2,256,476 ordinary shares and pre-funded warrants to Oramed.
Lifeward receives Nasdaq notice for audit committee non-compliance after director resignation
Audit committee reduced to two members following Hadar Levy's board resignation.
Lifeward posts Q4 revenue $5.1M (-33% YoY); enters Oramed deal for oral insulin platform
Q4 revenue $5.1M (-33% YoY); full year $22.0M (-14% YoY). ReWalk exoskeleton sales +20% in Q4.
Lifeward shareholders approve Oratech Pharma acquisition and related proposals
Proposal 1 passed: issuance of ordinary shares to Oramed for Oratech acquisition (1,854,591 for, 470,084 against).
Lifeward completes 1-for-12 reverse stock split to regain Nasdaq compliance
18.34M shares consolidated to ~1.53M shares; authorized shares increased from 75M to 100M.
Lifeward enters $525K secured note with Oramed at 24% interest, expandable by $975K
Initial principal $525,000; mutual consent can increase by up to $975,000 for total up to $1.5M.
Lifeward gets 180-day Nasdaq bid-price extension to Aug 3, 2026; 1-for-12 reverse split approved
Nasdaq gave Lifeward 180-day extension until Aug 3, 2026 to meet $1.00 bid price rule.
Lifeward schedules March 12 meeting to vote on Oratech acquisition from Oramed; board to expand to 8
EGM on March 12, 2026 to approve issuance of shares to Oramed as consideration for acquiring all of Oratech.
Lifeward acquires Oramed's POD tech; Oramed gets up to 49.99% LFWD stake; up to $47M capital
Issues Oramed shares & pre-funded warrants for 49.99% fully diluted equity (max 45% post-closing).
Lifeward Q3 revenue $6.2M (+1% YoY); net loss $0.20/shr; secures $3M loan from Oramed
Revenue $6.2M (+1% YoY); traditional products up 24% to $3.1M; AlterG down 15% to $3.1M.
Lifeward reports preliminary Q3 revenue $6.2M, cash $2.0M
Preliminary Q3 2025 revenue approximately $6.2 million, unaudited.
Lifeward Q2 revenue $5.7M (-15% YoY); net loss $6.6M; resets 2025 guidance
Revenue $5.7M, down 15% YoY; traditional product revenue $2.5M (-19% YoY) excluding one-time Medicare benefit.
Lifeward appoints Almog Adar as CFO, effective August 1, 2025
Almog Adar, previously VP of Finance and CAO, named CFO effective August 1, 2025.
Lifeward receives Nasdaq bid price deficiency notice; shares face potential delisting
Received Nasdaq notice on Aug 5, 2025; closing bid below $1.00 for 30 consecutive business days.
Proposal 5 failed: 811,866 for vs 993,112 against (excluding 3.4M broker non-votes).
Lifeward closes $2.6M public offering of 4M shares and warrants
Offering of 4M units at $0.65/unit, each consisting of 1 ordinary share + 1 warrant.
Lifeward appoints Mark Grant as President and CEO, effective June 2, 2025
Mark Grant will become CEO on June 2; Larry Jasinski serves as Co-CEO through June 30, then advisory through 2025.
Lifeward Q1 revenue $5.0M (-6% YoY); net loss narrows to $0.46/sh; reaffirms FY25 guidance $28-30M
Revenue $5.0M, down from $5.3M YoY; AlterG up 17% to $3.3M offset by ReWalk/restore drop.
Lifeward launches ReWalk 7 Personal Exoskeleton for U.S. market
ReWalk 7 now available nationwide for individuals with spinal cord injury.
Lifeward reports preliminary Q1 rev ~$5.0M, opex $6.5M-$6.7M; CSO terminated
Preliminary Q1 2025 revenue approximately $5.0 million; operating expenses expected between $6.5M and $6.7M.
Lifeward reports Q4 revenue $7.5M, full-year $25.7M; guides FY25 rev $28-30M
Q4 2024 revenue $7.5M (+10% YoY); full-year revenue $25.7M (+85% YoY).
Lifeward CEO Larry Jasinski to step down by Q2 2025; prelim FY2024 revenue $25.7M, opex $33.4M
CEO Larry Jasinski to depart by end of Q2 2025; will assist transition, treated as termination without cause.
Lifeward Q3 rev $6.1M (+39% YoY); net loss narrows to $3.1M; FY guidance $25M-$26M
Revenue $6.1M, up 39% vs $4.4M in Q3 2023; ReWalk sales up 173% to $2.5M.
Proposal to approve 2024 Incentive Compensation Plan failed: 432,879 for, 1,878,893 against.
Lifeward Q2 2024 revenue $6.7M (+400% YoY); net loss $0.50/shr, guidance reaffirmed
Revenue of $6.7M, up from $1.3M in Q2 2023; ReWalk historical product revenue rose 131%.
ReWalk Robotics Q1 2024 revenue surges 340% to $5.3 million, Medicare reimbursement drives growth
Q1 2024 revenue of $5.3 million, up 340% from $1.2 million in Q1 2023.
Lifeward reports record 2023 revenue $13.9M; Q4 rev $6.9M; FY2024 guidance $28-32M
Record annual revenue $13.9M for FY2023, up 151% from $5.5M in FY2022.
ReWalk granted Nasdaq compliance extension to March 30, 2024 citing CMS rule catalyst
Panel extended bid price compliance deadline from Jan 31 to March 30, 2024.
Larry Jasinski, a member of the Board and the Company’s Co-Chief Executive Officer, notified the Board of his decision to resign as a member of the Board, effective as of June 30, 2025.
appointed Mark Grant as a Class II director, effective June 15, 2025.
On June 2, 2025, Michael Lawless notified Lifeward Ltd. (the “ Company ”) of his resignation as Chief Financial Officer and Principal Financial Officer, effective as of June 27, 2025 or such earlier date as agreed upon by the Company and Mr. Lawless.
the Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) approved the appointment of Mark Grant as the Company’s President and Chief Executive Officer, effective June 2, 2025
Pursuant to notice provided on April 8, 2025, Charles Remsberg’s employment as the Chief Sales Officer of the Company will be terminated, effective May 30, 2025.
On February 19, 2025, the Company announced that Larry Jasinski will step down as the Chief Executive Officer of the Company and member of the Board of Directors of the Company (the “Board”), by the end of the second quarter of 2025.
appointed Robert J. Marshall Jr. to serve as a member of the Board, effective as of November 2, 2024
On June 27, 2024, the Board approved the appointment of Joseph Turk as chairperson of the Board, effective as of the Annual Meeting.
On June 27, 2024, Jeff Dykan, current Class I director of the Board of Directors (the “Board”) of ReWalk Robotics, Ltd. (the “Company”) and chairperson of the Board, notified the Board that he will retire and not stand for reelection at the Company’s 2024 Annual General Meeting of Shareholders (the “Annual Meeting”).
On April 18, 2024, the Board of Directors (the “Board”) of ReWalk Robotics Ltd. (the “Company”) increased the size of the Board from six (6) to seven (7) members, and appointed Michael Swinford to serve as a member of the Board, effective immediately.
the previously announced decision of Aryeh (Arik) Dan and Wayne B. Weisman, current Class III directors of the Board, not to stand for re-election at the Annual Meeting.
the previously announced decision of Aryeh (Arik) Dan and Wayne B. Weisman, current Class III directors of the Board, not to stand for re-election at the Annual Meeting.
Max materiality 0.90 · Median 0.60 · Most common event earnings